New York Daily News: MANHATTAN, NY – Drugmaker Pfizer and its German partner BioNTech on Wednesday revealed they would be submitting their coronavirus vaccine candidate for regulatory approval “within days” after their final analysis revealed the treatment was 95% effective with no major side effects.
The drug’s Phase 3 trial, now complete, confirmed the vaccine was consistently effective across age and ethnicity demographics. It comes just one week after a first round of results from the trial suggested the vaccine was just more than 90% effective, and days after Moderna said it preliminary phase three trial data showed efficacy for its treatment stood at about 94.5 percent.
“The final analysis underlines the results of the positive interim efficacy analysis announced on November 9,” BioNTech CEO Ugur Sahin said in a statement.
“The data indicates that our vaccine…is able to induce a high rate of protection against COVID-19 only 29 days after the first dose. In addition, the vaccine was observed to be well-tolerated in all age groups with mostly mild to moderate side effects, which may be due in part to the relatively low dose.”
- Top Feature Photo: This Dec. 4, 2017, file photo shows the Pfizer company logo at the company’s headquarters in New York. Pfizer is buying the cancer treatment company Array BioPharma in a deal worth $11.4 billion. Array has a combination therapy for BRAF-mutant metastatic melanoma, along with a pipeline of targeted cancer medicines in development and a portfolio of other medicines that are expected to generate significant royalties over time – AP Photo/Richard Drewm Fuke, File
